Literature DB >> 29617815

Resistance to Dolutegravir-A Chink in the Armor?

Daniel R Kuritzkes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29617815      PMCID： PMC6057516          DOI： 10.1093/infdis/jiy186

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  18 in total

1.  Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.

Authors:  Josep M Llibre; Chien-Ching Hung; Cynthia Brinson; Francesco Castelli; Pierre-Marie Girard; Lesley P Kahl; Elizabeth A Blair; Kostas Angelis; Brian Wynne; Kati Vandermeulen; Mark Underwood; Kim Smith; Martin Gartland; Michael Aboud
Journal:  Lancet       Date:  2018-01-06       Impact factor: 79.321

2.  Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks.

Authors:  Paul E Sax; Edwin DeJesus; Anthony Mills; Andrew Zolopa; Calvin Cohen; David Wohl; Joel E Gallant; Hui C Liu; Lijie Zhong; Kitty Yale; Kirsten White; Brian P Kearney; Javier Szwarcberg; Erin Quirk; Andrew K Cheng
Journal:  Lancet       Date:  2012-06-30       Impact factor: 79.321

3.  ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.

Authors:  Babafemi O Taiwo; Lu Zheng; Andrei Stefanescu; Amesika Nyaku; Baiba Bezins; Carole L Wallis; Catherine Godfrey; Paul E Sax; Edward Acosta; David Haas; Kimberly Y Smith; Beverly Sha; Cornelius Van Dam; Roy M Gulick
Journal:  Clin Infect Dis       Date:  2018-05-17       Impact factor: 9.079

4.  Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.

Authors:  Pedro Cahn; Anton L Pozniak; Horacio Mingrone; Andrey Shuldyakov; Carlos Brites; Jaime F Andrade-Villanueva; Gary Richmond; Carlos Beltran Buendia; Jan Fourie; Moti Ramgopal; Debbie Hagins; Franco Felizarta; Jose Madruga; Tania Reuter; Tamara Newman; Catherine B Small; John Lombaard; Beatriz Grinsztejn; David Dorey; Mark Underwood; Sandy Griffith; Sherene Min
Journal:  Lancet       Date:  2013-07-03       Impact factor: 79.321

5.  HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy.

Authors:  Ingeborg E A Wijting; Cynthia Lungu; Bart J A Rijnders; Marchina E van der Ende; Hanh T Pham; Thibault Mesplede; Suzan D Pas; Jolanda J C Voermans; Rob Schuurman; David A M C van de Vijver; Patrick H M Boers; Rob A Gruters; Charles A B Boucher; Jeroen J A van Kampen
Journal:  J Infect Dis       Date:  2018-07-24       Impact factor: 5.226

6.  The S230R Integrase Substitution Associated With Virus Load Rebound During Dolutegravir Monotherapy Confers Low-Level Resistance to Integrase Strand-Transfer Inhibitors.

Authors:  Hanh T Pham; Lydia Labrie; Ingeborg E A Wijting; Said Hassounah; Ka Yee Lok; Inna Portna; Mark E Goring; Yingshan Han; Cynthia Lungu; Marchina E van der Ende; Bluma G Brenner; Charles A Boucher; Bart J A Rijnders; Jeroen J A van Kampen; Thibault Mesplède; Mark A Wainberg
Journal:  J Infect Dis       Date:  2018-07-24       Impact factor: 5.226

7.  Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Authors:  Jeffrey L Lennox; Raphael J Landovitz; Heather J Ribaudo; Ighovwerha Ofotokun; Lumine H Na; Catherine Godfrey; Daniel R Kuritzkes; Manish Sagar; Todd T Brown; Susan E Cohn; Grace A McComsey; Francesca Aweeka; Carl J Fichtenbaum; Rachel M Presti; Susan L Koletar; David W Haas; Kristine B Patterson; Constance A Benson; Bryan P Baugh; Randi Y Leavitt; James F Rooney; Daniel Seekins; Judith S Currier
Journal:  Ann Intern Med       Date:  2014-10-07       Impact factor: 25.391

8.  Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.

Authors:  Ingeborg Wijting; Casper Rokx; Charles Boucher; Jeroen van Kampen; Suzan Pas; Theodora de Vries-Sluijs; Carolina Schurink; Hannelore Bax; Maarten Derksen; Eleni-Rosalina Andrinopoulou; Marchina van der Ende; Eric van Gorp; Jan Nouwen; Annelies Verbon; Wouter Bierman; Bart Rijnders
Journal:  Lancet HIV       Date:  2017-10-26       Impact factor: 12.767

9.  Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study.

Authors:  Bonaventura Clotet; Judith Feinberg; Jan van Lunzen; Marie-Aude Khuong-Josses; Andrea Antinori; Irina Dumitru; Vadim Pokrovskiy; Jan Fehr; Roberto Ortiz; Michael Saag; Julia Harris; Clare Brennan; Tamio Fujiwara; Sherene Min
Journal:  Lancet       Date:  2014-04-01       Impact factor: 79.321

10.  Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile.

Authors:  Manuel Tsiang; Gregg S Jones; Joshua Goldsmith; Andrew Mulato; Derek Hansen; Elaine Kan; Luong Tsai; Rujuta A Bam; George Stepan; Kirsten M Stray; Anita Niedziela-Majka; Stephen R Yant; Helen Yu; George Kukolj; Tomas Cihlar; Scott E Lazerwith; Kirsten L White; Haolun Jin
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191
View more
  3 in total

1.  Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.

Authors:  Beatriz Grinsztejn; Michael D Hughes; Justin Ritz; Robert Salata; Peter Mugyenyi; Evelyn Hogg; Linda Wieclaw; Robert Gross; Catherine Godfrey; Sandra W Cardoso; Aggrey Bukuru; Mumbi Makanga; Sharlaa Faesen; Vidya Mave; Beatrice Wangari Ndege; Sandy Nerette Fontain; Wadzanai Samaneka; Rode Secours; Marije van Schalkwyk; Rosie Mngqibisa; Lerato Mohapi; Javier Valencia; Patcharaphan Sugandhavesa; Esmelda Montalban; Anchalee Avihingsanon; Breno R Santos; Nagalingeswaran Kumarasamy; Cecilia Kanyama; Robert T Schooley; John W Mellors; Carole L Wallis; Ann C Collier
Journal:  Lancet HIV       Date:  2019-07-29       Impact factor: 12.767

2.  Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.

Authors:  Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Kaitlin Anstett; Thibault Mésplède; Jean-Pierre Routy; Marjorie A Robbins; Bluma G Brenner
Journal:  Retrovirology       Date:  2018-08-17       Impact factor: 4.602

3.  Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis.

Authors:  Mario Cruciani; Saverio G Parisi
Journal:  PLoS One       Date:  2019-09-10       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.